• Upcoming investor conferences

    December 11, 2017
    Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the first quarter of 2018: J.P. Morgan Annual...
  • Innate Pharma announces its financial calendar for 2018

    December 7, 2017
    Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2018, which is set as follows: March 8, 2018: Publication of 2017 financial statements...
  • Innate Pharma provides an update on Lirilumab

    November 22, 2017
    Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb The combination of...
  • Third quarter 2017 report

    November 15, 2017
    Cash, cash equivalents and financial assets amounting to €195.7 million Robust cash position allows for further investment in portfolio of proprietary immuno-oncology programs Innate Pharma continues...